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Abstract 
      Parkinson’s disease (PD) is known to be a chronic 
and progressive neurodegenerative disease caused by 
a selective degeneration of dopaminergic (DAergic) 
neurons in the substantia nigra pars compacta (SNc). 
A large body of experimental evidence indicates that 
the factors involved in the pathogenesis of this disease 
are several, occurring inside and outside the DAergic
neuron. Recently, the role of the neuron-glia interaction
and the inflammatory process, in particular, has been 
the object of        intense study by the research community.
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It seems to represent a new therapeutic approach opportunity for this 
neurological disorder. Indeed, it has been demonstrated that the 
cyclooxygenase type 2 (COX-2) is up-regulated in SNc DAergic neurons in 
both PD patients and animal models of PD and, furthermore, non-steroidal 
anti-inflammatory drugs (NSAIDs) pre-treatment protects against 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6 hydroxydopamine (6-OHDA)-
induced nigro-striatal dopamine degeneration. Moreover, recent 
epidemiological studies have revealed that the risk of developing PD is 
reduced in humans who make therapeutical use of NSAIDs. Consequently, it is 
hypothesized that they might delay or prevent the onset of PD. However, 
whether or not these common drugs may also be of benefit to those individuals 
who already have Parkinson’s disease has not as yet been shown.  
 In this paper, evidence relating to the protective effects of aspirin or other 
NSAIDs on DAergic neurons in animal models of Parkinson’s disease will be 
discussed. In addition, the pharmacological mechanisms by which these 
molecules can exert their neuroprotective effects will be reviewed. Finally, 
epidemiological data exploring the effectiveness of NSAIDs in the prevention 
of PD and their possible use as adjuvants in the therapy of this 
neurodegenerative disease will also be examined. 
 
Introduction 
 Parkinson’s disease (PD) is the most prevalent neurological disorder of the 
basal ganglia, and it is characterized by a progressive loss of dopaminergic 
(DAergic) neurons in the caudate nucleus, putamen and substantia nigra (SN) 
[1,2]. The loss of DAergic neurons in the substantia nigra pars compacta (SNc) 
is the principal feature of PD [3] and results in cardinal motor symptoms such 
as tremor at rest, bradykinesia, muscular rigidity, stooped posture and 
instability [4]. Hitherto, despite the recent progress in understanding the 
etiopathogenesis of PD, the modalities whereby the neurodegenerative process 
begins and progresses are still unclear. Furthermore, the situation is 
complicated by the large number of factors that seem to be involved in the 
onset of this disease, such as aging, genetic vulnerability, exogenous or 
endogenous toxins, hydroxyl radicals (.OH) production, neuronal metabolic 
disturbances and inflammation [4-8]. Thus, the cumulative neuronal insults 
attributable to these metabolic stress factors may promote premature SNc 
DAergic degeneration through the activation of apoptotic programs [9-11]. 
However, the specifics and sequential neuroapoptotic events associated with 
premature, progressive SNc neuronal atrophy remain undefined.  
 Thus far, among the various accepted experimental models of PD, 
neurotoxins still represent the most  popular tools to produce selective death of 
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DAergic  neuron  both in vitro and in vivo systems. Even though recent genetic 
discoveries have lead to a number of different genetic models of PD, none of 
these shows the typical degeneration of DAergic neurons [12,13]. Among the 
neurotoxins, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a product 
of synthetic meperidine derivative, and 6-hydroxydopamine (6-OHDA), 
hydroxylated dopamine derivatives are the most used for inducing 
parkinsonian features in cells and animal species. MPTP is metabolized to the 
1-methyl-4-phenylpyridinium ion (MPP+) by monoamine oxidase-B (MAO-B) 
[14]. This highly toxic metabolite is selectively taken up into dopaminergic 
neurons, via the DA transporter [15], where it provokes an intracellular 
accumulation of Ca2+, thus interfering with the function of nerve terminals in 
the striatum [16] and inhibits complex 1 (NADH-ubiquinone oxidoreductase) 
of the respiratory chain causing progressive cell death [17]. On the other hand, 
the neurotoxic effects of 6-OHDA are mediated by the generation of .OH, pro-
inflammatory mediators or pro-apoptotic agents [18-20]. The result of the 
administration of each neurotoxin, although by different mechanisms, is DA 
depletion in the nigro-striatal pathway of laboratory animals and molecular 
alterations comparable to those seen in PD’s patients [21]. Recently, it has 
been shown that 6-OHDA, MPTP as well the bacterial lipopolysaccharide 
(LPS) induce the death of DA cells activating an immune response [22-24]. 
These animal models have been crucial in the study of PD and have allowed 
the formulation of different hypotheses about its etiopathogenesis, and 
recently, they have been utilized to determine the role of inflammation in DA 
neuronal death. Moreover, toxin-based models have been useful in developing 
neuroprotective and neurorestorative strategies and in testing new drugs for the 
treatment of this disorder. In this review, experimental data regarding the role 
of neuroinflammation in the aetiology of PD, the effect of non-steroidal anti-
inflammatory drugs (NSAIDs) and the possibility for their use as a new 
therapeutic approach for this neurodegenerative disease will be reviewed.  
 
Inflammation in Parkinson’s disease 
 Thus, decades of research on the aetiology of Parkinson’s disease has 
resulted in much information, but little has been gained in establishing the 
events causing the initiation and progression of the disease. Recently, the 
involvement of neuroinflammation and microglial activation in the 
pathogenesis of PD has been emphasized [25,26]. Results of neurotoxin 
models of PD, corroborating findings obtained in transgenic animal models 
and epidemiological studies, strongly support the hypothesis that this 
neurodegenerative disease is not purely neuronal, as it has been previously 
considered [27,28]. Thus, DAergic neuronal degeneration is the likely result of 
multiple pathogenic factors occurring both within and outside the cell. The 
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cross-talk between neurons and glia is becoming more and more important for 
the understanding of brain pathophysiology. This new finding, unfortunately, 
does not allow us to diagnose the disease any earlier because the neuroinflammatory 
process is silent and unnoticed due to the absence of pain fibres in the brain, 
but it at least gives a glint of hope for new potential therapeutic targets for the 
slowing of neuronal degeneration. 
 Neuroinflammation is not a distinctive characteristic of PD but it has been 
clearly revealed in a broad spectrum of neurodegenerative diseases that share 
with it a common pathological process, such as Alzheimer’s disease (AD), 
Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and multiple 
sclerosis (MS) [26,29]. The scenario is still obscure, but inflammation in PD is 
not any longer considered a non-specific consequence of neuronal 
degeneration as it was originally thought to be. Indeed, neuroinflammation 
may aggravate the course of the disease and, as it has recently been suggested, 
may be a primary factor in some cases of PD [8,26,27,30]. Indeed, postmortem 
examinations have shown that neuronal degeneration in PD is associated with 
massive gliosis due to a subset of activated glial cells, the microglia [31-33], 
evidence that has been confirmed in MPTP-induced parkisonism in monkeys 
[34] and humans [35]. Interestingly, the SN, usually prone to the deleterious 
effects of oxidant stress, containing DA neurons high in iron and low in 
glutathione [8,36], is also one of the brain regions more sensitive to 
inflammation. Indeed, healthy SN exhibits the highest concentration of 
microglia in the brain especially in the ventral tier of the pars compacta 
[37,38]. Normally, very few microglial cells are detected in the vicinity of 
DAergic neurons, and when present, they appear to be resting with fine, long 
processes. Neuronal damage, aggregated proteins with abnormal 
conformations present in Lewy bodies and other unknown factors increase the 
number and change the shape of glial cells, to such an extent that they can be 
found in proximity to DA cells with short cellular processes [39]. Activated 
microglia are recruited to the SNc from various structures and finally stuck to 
DA neurons. It has been shown that glial cells once activated become 
phagocytes that ingest degenerating DA neurons piece-by-piece. This occurs 
early in neuronal degeneration, starting at the extending fibres, such as the 
neurite which extend into the SN reticulata [40]. Hence, activated glial cells 
release detrimental compounds such as, interleukin (IL)-1β, IL-6, tumor 
necrosis factor- α (TNF-α) and interferon γ (IFN- γ), which may act by 
stimulating inducible nitric oxide synthase (iNOS), or which may exert a more 
direct deleterious effect on DAergic neurons by activating receptors that contain 
intracytoplasmic death domains involved in apoptosis [24,33,41-48]. Microglia 
can also induce neuritic    beading [49] or   synaptic stripping    along dendrites [50] 
Inflammation and PD 163 
leading to synaptic disconnection and loss of trophic support and cell death 
[51,52]. Animal studies using MPTP have shown that the immune reaction might 
evolve, ultimately leading to the infiltration of lymphocytic CD4+ and CD8+ T 
cells into the injured SN and striatum, given that glial cells are potent activators 
in lymphocyte invasion. Moreover, activated lymphocytes present in the SN 
could start an immune-mediated inflammation [47,48].  
 Nevertheless, such activation of microglia is not only disadvantageous to 
neurons. Indeed, some investigations indicate that activated microglial cells 
and macrophages tend to synthesise and produce neurotrophic factors (brain-
derived neurotrophic factor, BDNF and glia-derived neurotrophic factor, 
GDNF) through certain compensatory mechanisms following neuronal injury 
and induce sprouting surrounding the wound in the striatal DA terminals 
[53,54]. Moreover, activated glia play a role in gradually removing the dead 
DA neurons as a defence mechanism, although some healthy DA neurons 
might be also phagocytosed during the process [9,55]. Therefore, inflammation 
has been rightly defined as a double-edged sword. It normally starts as a 
defence reaction but, for the failure of its control mechanism, can lead to an 
uncontrolled and continuous extremely damaging immune response. A brief 
pathogenic insult, furthermore, can induce an ongoing inflammatory response 
and the toxic substances released by the glial cells may be involved in the 
propagation and perpetuation of neuronal degeneration. This theory is 
plausible, corroborated by the evidence that several years after the exposure to 
MPTP, increased levels of factors such as, interleukin (IL)-1β, IL-6 and tumor 
necrosis factor- α (TNF-α) have been found in the basal ganglia and cerebral 
spinal fluid (CSF) of patients with toxin-induced PD [25].  
 A prominent factor in neuroinflammatory reactions in PD seems to be the 
activation of the complement system [56-58] a major mediator of 
immune/inflammation reactions. Indeed, increased mRNA levels of 
complement components have been found in affected brain regions [28]. The 
presence of complement components, including all constituents of the 
membrane attack complex (MAC), has been shown intracellularly on Lewy 
bodies and on oligodendroglia in the SN of PD patients [59-61]. Accumulation 
of Lewy bodies can apparently cause the activation of complement, the 
initiation of reactive changes in microglia, and the release of potentially 
neurotoxic products such as the MAC, .OH, and excess glutamate (GLU) [62].  
 So far, among the plethora of toxic factors released by the reactive glia it is 
not clear which one of them is responsible for the DAergic neuronal death. 
Reactive oxygen species (ROS), .OH, NO and its peroxinitrite (ONOO- ), are 
the likely candidates. From this evidence it appears clear that inflammatory 
process and oxidative stress derived from DA metabolism, constitute a vicious 
cycle that lead to the final demise of nigral DA cells (Fig. 1) [27]. 
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Figure 1. Classical versus non-classical effects of NSAIDs. Abbreviations: COX 
cyclooxygenase; PLA2, phospholipase A2; PGG2, Prostaglandin G2; PGH2, Prostaglandin H2; 
Prostaglandin F2alha, PGF2α; Prostaglandin D2, PGD2; Prostaglandin I2, PGI2; Prostaglandin 
E2, PGE2; Thromboxanes, TXs; Nuclear Factor kappa B, NF-κB; Peroxisome proliferator-
activated receptor gamma, PPARγ; Inducible nitric oxide synthase, iNOS; c-Jun N-terminal 
kinases, JNKs ; Extracellular signal-regulated kinases, ERKs; P38 mitogen-activated protein 
kinases, p38 kinases; factor activator protein 1, AP-1. 
 
Furthermore, experimental evidence has also shown that inflammatory loss of 
DA nigro-striatal neurons might be mediated by apoptosis [63-67]. Indeed, 
inflammation  induced  by  intranigral  injection  of  LPS could be mediated, at 
least in part, by the mitogen-activated protein kinase p38 (MAPK p38) signal 
pathway leading to activation of inducible nitric oxide synthase (iNOS) and 
cysteine protease caspase-11 [64]. According to this evidence, it has been recently 
shown that LPS-induced inflammation causes apoptosis in the SNc due to 
increased pro-inflammatory cytokine levels of mRNA for TNF-α, IL-1α, IL-1β and 
IL-6, and the apoptosis-related genes Fas and Bax and caspase-3 immunoreactivity 
[63]. These data have been confirmed also in a MPTP mouse model, neurotoxic 
effect seems to be mediated via activation of the caspase-11 cascade and 
inflammatory cascade, as well as the mitochondrial apoptotic cascade [65].  
 Furthermore, the link between inflammation and apoptotic signalling cascade 
could follow other pathways. Thus, in a chronic MPTP model of PD, activation of 
the nuclear transcription factor NF-κB, that is well-known for its role in preventing 
apoptotic cell death, has been revealed [68], this in turn, promotes the synthesis of 
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cyclooxygenase types 2 (COX-2) [69]. COX-2 induction, increases inflammatory 
response with ROS formation by the arachidonic acid (AA) cascade, thus 
triggering a vicious circle (Fig. 1). The release of AA also inhibits GLU uptake 
contributing to the neurodegenerative processes seen in PD [70]. In addition, COX-
2 could also be induced by pro-inflammatory cytokines such as TNF α  via the c-
Jun N-terminal kinase (JNK) pathway [33,71,72].  
 
Old and new mechanisms of action for NSAIDs  
 The above discussion makes it plausible that drugs with the capacity to 
rescue DA neurons from microglia toxicity and inflammatory processes, may 
result in an amelioration of parkisonian symptoms by delaying the onset and 
slowing the progression of the disease [30,73,74]. Several agents have been 
shown to inhibit microglial or monocytic cell neurotoxicity [73,75]. Among 
them much attention has been devoted to NSAIDs since it has been shown by 
experimental and clinical observation that they may represent a possible new 
therapeutic approach for treating PD. 
 
 NSAIDs are an heterogeneous group of compounds which share many 
pharmacological properties (and side effects) and are the main drugs used as 
analgesics and antipyretics to reduce the untoward consequences of 
inflammation. NSAIDs together with steroidal anti-inflammatory drugs 
(SAIDs) are capable of halting eicosanoids synthesis and suspending 
inflammatory process progression. SAIDs, which include both cortisone and 
its derivatives, inhibit phospholipase A2 (PLA2 ) blocking both the production 
of LTs and PGs via the discontinuance of AA synthesis. Differently, NSAIDs 
only inhibit COX activity inducing a diminution of PGs levels, accompanied 
by a compensatory increase of LTs levels (Fig. 2).  
 
 The NSAIDs can be classified into three groups based on their COX 
inhibition ratios (affinity of inhibition for COX-1 or COX-2) chemical 
structures or inhibitory kinetics [76] (Table 1). 
 
  Recently, a new class of NSAIDs has been synthesized named nitric oxide-
donating nonsteroidal anti-inflammatory drugs (NO-NSAIDs), consisting of a 
traditional NSAID to which a NO releasing moiety is covalently attached, that may 
have an important role in colon cancer prevention and/or treatment [77]. The main 
pharmacological action of these compounds is on the metabolism of AA inhibiting 
the enzymes possessing COX activity (Fig. 2) [78]. Whenever an inflammatory 
process occurs, there is a consequent activation of specific enzymes in the cell 
wall. Among them, one of the first activated is PLA2 phospholipase A2 (PLA2 ) that 
deacylates fatty acids from the 2nd carbon atom of the triglyceride backbone of 
mambrane phospholipids, producing AAs and lyso-phospholipids [79-81]. AA 
is subjected to the action of two families   of enzymes: lipoxygenases (LOX) and 
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Figure 2. Interacting synergistic mechanisms involved in dopaminergic death in 
Parkinson’s disease. The role of the positive feed back (vicious) circle between neurononal 
death, neuroinflammation and/or oxidative stress is depicted. Abbreviations: Dopamine, DA; 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP; 6 hydroxydopamine, 6-OHDA; 
Methamphetamine, METH; lipopolysaccharide, LPS. 
 
COX. These enzymes are able to insert oxygen into the molecule of AA in a 
specific way, producing five prostanoids: PGE2, PGF2, PGD2, PGI2 (prostacyclin),  
and  thromboxane A2 (TxA2) through the intermediate      PGH2. These prostanoids 
bind to specific G-protein-coupled receptors designated EP (for E-prostanoid), FP, 
DP, IP, and TP receptors, respectively [82,83]. LTs are commonly known as 
vasoconstrictor and bronchospastic agents whereas PGs play a pivotal role in all 
the biochemical mechanisms inducing pain, hyperpyrexia and classical signs of 
inflammation, cytoprotective and citotoxicity processes. Bergstrom and colleagues 
[84] first described PGs in the brain more than 40 years ago. Since then, 
numerous studies have shown that PGs are formed in certain regions       of the 
brain and in the spinal cord as a response to a variety of stimuli and in 1976 the 
enzyme which is key in the synthesis of PGs from AA, COX, was purified 
[85]. Subsequent to the cloning of the COX-1 gene, Dan Simmons   and 
colleagues identified a second gene with COX activity (COX-2) [86]. 
Recently, a third  variant  of  COX has  been  described, initially        called COX-3  
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Table 1. Biological, pharmacokinetic and chemical subdivision of NSAIDs. 
 
COX-2/COX-1 RATIO INHIBITION 
 KINETICS 
CHEMICAL STRUCTURE 
Nonselective COX inhibitors 
(e.g. ketorolac or piroxicam,  
with ratio ≈1); 
simple, competitive 
(e.g. ibuprofen and  
Naproxen) 
Carboxylic acids 
(e.g.Aspirin 
and Ibuprofen) 
Selective COX-1 inhibitors 
(e.g. Dexketoprofene and 
SC 560 with ratio < 0.01) 
 
competitive, time- 
dependent, reversible 
(e.g.  Indomethacin and 
DuP 697) 
Pyrazoles 
(e.g.Phenilbutazone and 
Kebuzone) 
Preferential COX-2 inhibitors 
(e.g. ibuprofen 
and indomethacin,  
with ratio 15-60) 
competitive, time- 
dependent, irreversible 
(e.g. Aspirin and 
Valeryl salicylate) 
Oxicams 
(e.g. Piroxicam and 
Isoxicam) 
Selective COX-2 inhibitors  
(e.g. coxibs, selective COX-2, with 
ratio >1000) 
 Sulphonamides 
(e.g. Valdecoxib and 
Celecoxib) 
  Methylsulphones 
(e.g. Rofecoxib and 
Etoricoxib) 
  Arylacetic acid 
(e.g. Lumiracoxib) 
 
[87,88], that might be the target of acetaminophen (paracetamol) [87-88]. 
COX-3 has been more appropriately renamed COX-1b being a splice variant 
of COX-1which has retained intron-1 during translation [88]. It has a  
completely different amino acid sequence than the known cyclooxygenases 
and it does not seem to show cyclooxygenase activity in mice [89] and rats 
[90], thus it may well be that COX-1b is not relevant to humans. 
 The properties of COX-1 are different to those of COX-2. It was originally 
thought that the function of constitutive COX-1 was involved in physiological 
phenomena, such as cytoprotection of the stomach, platelet aggregation, and 
kidney functions, whereas that of COX-2 was involved in various pathologies. 
However, recent studies suggest that the inducible isoform COX-2 also plays 
important role in development and homeostasis [91]. In the central nervous system 
(CNS), COX-2 plays an important role in membrane excitability, synaptic 
transmission and participates in memory consolidation during REM sleep [92,93]. 
 COX-1 and COX-2 are widely and both constitutively expressed under 
normal physiological conditions in human organs [94], even though only 
COX-2 is dramatically up-regulated during inflammatory processes. Similarly 
to the other tissues, the two isoforms are distributed heterogeneously among 
the brain cells, COX-1 and COX-1b are detected in microglial cells, while 
COX-2 is found in neuronal and glial cells, astrocytes do not express 
significant COX levels [95,96]. Normally, COX-2 is expressed in low levels in 
nigral DA neurons, but it becomes up-regulated in both patients and 
experimental PD models [22-24,33,97-99]. 
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 COX-2 expression in neurons has been proposed to increase the 
vulnerability of neurons to GLU mediated excitotoxicity. In the CNS, COX-2 
expression is increased in neurons following GLU receptor activation [100-
102] and is thought to contribute to increased neuronal death. Genetic evidence 
also indicates that neuronal expression of COX-2 leads to excitotoxic cell 
death. Transgenic mice that overexpress neuronal COX-2 are more susceptible 
to excitotoxic cell death [103] and age associated neuronal loss [104]. This 
evidence has been confirmed in rat ischemic hippocampus, where COX-2 
expression was substantially and significantly upregulated in vulnerable CA1 
and not in resistant CA3 and dentate granule cells [105]. In contrast, COX-2 
null (knockout) mice exhibit less neuronal death following ischemia, challenge 
with NMDA [106], and MPTP [22,98,99,107]. Pharmacological and genetic 
inhibition of COX-2 is capable of sheltering DA neuronal bodies in the SNc as 
well as the striatal TH-stained fibres against toxin effects, suggesting a 
protection of the entire nigrostriatal pathway [22]. Potential downstream 
effectors of COX-2 neurotoxicity on SNc DA neurons are PGE2 and .OH 
generated through peroxidase activity, levels of which have been found to be 
enhanced in experimental models and in PD post-mortem samples 
[22,33,97,108]. PGE2 mediates COX-2 neurotoxicity essentially through the 
activation of EP1/EP3 receptors that disrupt Ca2+ homeostasis by incresing its 
cellular concentration thus causing excitotoxic neuronal death [102,109]. 
Conversely, the activation of the prostanoid EP2/EP4 G-protein-coupled 
receptors seems normally to be associated with neuroprotection [110,111]. 
PGE2 is present in ventral midbrain neurons and derives primarily from COX-
1 [33]. After a few days of neuronal insult, PGE2 concentration almost doubles 
due to MPTP-induced COX-2 up-regulation, although more than half still 
depends on COX-1 activity [33]. Microglia-DAergic neurons interaction is 
necessary for MPP+-induced COX-2 activation and PGE2 production [23]. The 
toxin first induces reactive microgliosis and secretion of its proinflammatory 
factors, among them PGE2. These will enhance COX-2 DA neuronal activity 
and lead to a second wave    of neuronal damage, which in turn, could 
reinforce the microgliosis process. The strong correlations found between 
COX-2 and PGE2 levels, microglial activation and dopaminergic 
neurodegeneration suggest that COX-2 may mediate microglial activation and 
may play a key role in amplifying the inflammatory response and other toxic 
effects in a vicious circle, which ultimately exacerbates dopaminergic neuronal 
loss (Fig. 1) [22,23,33,40]. 
  Moreover, COX-2 activation might result in direct DAergic cell demise by 
producing the neurotoxic oxidant species DA-quinone [33,112], and by 
increasing DNA damage inducing the formation of etheno-DNA adducts that 
arise as a consequence of COX-2-mediated lipid peroxidation [113,114].  
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 Aspirin (acetylsalicylic acid, ASA) is the most frequently used drug in the 
world to treat inflammation and pain. Aspirin is the progenitor of the NSAIDs 
family, it is known to preferentially inhibit COX-1 rather than COX-2 in an 
irreversible way, by acetylating the active site of these enzymes, producing 
salicylic acid (SA) [80,115]. Although many of ASA’s and other NSAIDs’ 
pharmacological actions are related to the ability to inhibit prostaglandin 
biosynthesis, some of their beneficial therapeutic effects are not completely 
understood. NSAIDs are able to inactivate the transcription factors NF-κB and 
factor activator protein 1 (AP-1) which is critical for the induction of 
neoplastic transformation and the induction of multiple genes involved in 
inflammation and infection [115-121]. Diverse noxious cellular stimuli free 
NF-κB from any endogenous inhibitor, permitting the translocation of free NF-
κB from the cytoplasm to the nucleus. Consequently, NF-κB binds to DNA 
and activates a number of genes involved in the inflammatory and immune 
responses. Some of these gene products, such as TNF could exert cytotoxic 
effects by switching on apoptotic self-destruct programs [122,123]. ASA and 
COX-2 selective inhibitors exert antitumor effects partly through blocking AP-
1 activation. AP-1, consisting of Jun/Fos dimers, is a downstream target of 
MAP kinase family members including extra-cellular signal regulated kinases 
(ERK-1 and -2; p42/p44 MAPK), Jun kinases (JNK), and p38 MAPK. NSAIDs 
suppress AP-1 activation through different mechanisms blocking the activation 
of ERK and JNK as well as P38 mitogen-activated protein kinase (p38 kinase) 
[118,124]. Furthermore, ASA and salicylate at therapeutic concentrations inhibit 
COX-2 protein expression pointing towards a possible (cell-specific) target of 
NSAIDs upstream to COX-2 enzyme activity through interference with the 
binding of CCAAT/enhancer binding protein beta (C/EBPbeta) to its cognate site 
on COX-2 promoter/enhancer. Expression of other genes, such as iNOS and 
interleukin-4, may be inhibited by ASA and salicylate through a C/EBP-
dependent mechanism or inhibiting NF-κB activation [125,126].  
 Among the COX independent actions, it has been shown that NSAIDs in 
neuronal cells, might directly and dose-dependently scavenge ROS and 
reactive nitrogen species (RNS) blocking their detrimental effects [117,127]. 
Moreover, the agonistic activity shown at high concentration by some NSAIDs 
such as ibuprofen and indomethacin toward the peroxisome proliferator-
activated receptor-γ (PPARγ) seems relevant to neuroprotection [128]. This 
receptor PPARγ is a ligand-activated inhibitory transcription factor that 
antagonizes the activity of NF-κB, AP-1, signal transducer and activator of 
transcription 1 (STAT-1) and nuclear factor of activated T cells (NFAT) 
[129,130]. Its cellular activation is associated with a reduction in the 
expression of several inflammatory genes [131] and the production of 
inflammatory cytokines (i.e., IL-1, IL-6, TNF) [130]. In vitro studies have 
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shown that the selective agonists pioglitazone, indomethacin and ibuprofen can 
activate PPARγ in microglia, reducing the Aβ-mediated secretion of 
inflammatory cytokines and neurotoxicity, decreasing the number of activated 
microglia and reactive astrocytes [132,133]. Drug treatment reduces the 
expression of the proinflammatory enzymes COX-2, iNOS and beta-secretase-
1 (BACE1) mRNA and protein levels [133]. In addition, PPARγ depletion 
potentiates beta-secretase mRNA levels by increasing BACE1 gene promoter 
activity. Conversely, overexpression of PPARγ, as well as NSAIDs and 
PPARγ activators, reduced BACE1 gene promoter activity. These recent 
results suggest that PPARγ could be a repressor of BACE1 binding to a PPRE 
located in the BACE1 gene promoter. These effects may explain the 
overexpression of BACE1 in the brain under inflammatory conditions and 
emphasize the hypothesis that neuroinflammatory mechanisms significantly 
contribute to the pathogenesis of AD. This could be a potential mechanism by 
which NSAIDs have a protective effect against the development of AD [134]. 
 Currently, selective COX-2 inhibitors are used more frequently than the 
other NSAIDs because they produce the same pharmacological effects as non 
selective COX inhibitors without the attendant COX-1 inhibition related toxic 
effects on stomach lining. Unfortunately, this class of drugs has recently been 
shown to increase the risk of cardiovascular events. As a result, some of these 
drugs have been withdrawn from the market and some clinical trials halted, 
among them a trial with celecoxib in AD [135].  
 
Neuroprotective effects of NSAIDs in Parkinson’s 
disease: Experimental evidence 
 Since the end of the 1980s, when McGeer and colleagues [31] in their 
seminal study reported a large number of reactive leucocyte antigent-DR 
(HLA-DR)-positive microglial cells in the SNc and striatum of patients with 
PD, several experimental investigations have provided further plausible 
evidence for the activation of a proinflammatory response in this disease. 
The importance of the subject, has engaged several groups in the emerging 
and promising theme of NSAIDs and neurodegeneration. As far as we are 
aware, nineteen studies have been carried out in which the effects of NSAIDs 
have been tested on animal (mouse and rat) models of PD and cell cultures 
(Table 2). This evidence supports the use of NSAIDs in reducing the 
pathological burden of the disease; ASA was the most tested drug (8 
studies), followed by its metabolite SA (5 studies), only 1 studied the effect 
of COX-1 but 10 focused on the role of COX-2 using selective inhibitors for 
this isoform of the enzyme. The results of ten years of research will be 
reported chronologically. 
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 The first piece of experimental evidence in the field was published by 
Grilli and co-workers a few years after the McGeer study [117]. These authors 
showed  that  ASA  and  its  metabolite  SA,  at   concentrations compatible with               
amounts in plasma during treatment of chronic inflammatory states, were 
protective against neurotoxicity elicited by GLU in primary cultures of rat 
cerebellar  granule  cells  and  hippocampal  slices,  whereas       indomethacin was 
unable  to  prevent  GLU-induced cell death. The common molecular target for 
 
Table 2. Experimental studies with NSAIDs. 
 
Experimental model NSAIDs Outcome 
primary cultures of rat 
cerebellar granule cells and  
hippocampal slices [117] 
ASA (1, 3 mM) SA (3,10 
mM)indomethacin (1-
20µM)  
Protection ↓NF-κB 
Protection ↓NF-κB 
NO protection 
MPTP mouse model  
of PD, MPTP 
(15 mg/kg, s.c.) [136].  
ASA (100 mg/kg) 
Aspegic (200 mg/kg) 
SA (100 mg/kg) 
Paracetamol (100 
mg/kg) Diclofenac (100 
mg/kg) 
Ibuprofen (20 mg/kg) 
Indomethacin (100  
mg/kg) 
Protection ROS scavenging 
Protection ROS scavenging 
Protection ROS scavenging  
NO protection 
NO protection 
NO protection 
NO protection 
MPTP mouse (C57BL/6)  
model of PD, MPTP 30  
mg/kg or 40 mg/kg s.c. [140]. 
SA (50 mg/kg or 100  
mg/kg i.p.) 
Protection ROS scavenging 
MPTP mouse model  
of PD, MPTP (30 mg/kg 
i.p. twice, 16 h apart) 138]. 
SA (25-100 mg/kg, i.p.) Protection ROS 
scavenging ↓akinesia or 
catalepsy  
Cultured primary rat  
embryonic neurons  
from mesencephalon 
GLU-toxicity [139]. 
ASA (1 mM) 
Paracetamol (1 mM) 
Ibuprofen (0.1 mM) 
Protection ??Mechanism 
Protection ??Mechanism 
Protection ??Mechanism 
MPTP mouse (C57BL/6) 
model of PD, MPTP 
(30 mg/kg s.c.) [33] 
ASA (10, 50, 100 
mg/kgi.p.). Meloxicam (2, 
7.5,50  mg/kg i.p.) 
Protection ↓COX-1/ 
COX-2 ↓akinesia or 
catalepsy Protection  
↓COX-2 ↓akinesia or catalepsy 
Cultured primary rat 
embryonic neurons 
from mesencephalon  
6-OHDA (1.25-25 µM) 
MPP+ (0.625-20 µM) 141]. 
 
 
ASA (1 mM) 
ASA (1 mM)  
 
 
Protection ??Mechanism 
Protection ??Mechanism 
MPTP mouse model  
of PD [142]. 
Indomethacin 
(1 mg/kg, i.p.) 
Protection ↓ inflammation 
MPP+ rat model of 
PD, intrastriatal 100nmol (in 4 
µl/animal) [143]. 
SA (50 and 100 
mg/kg, i.p.), diclofenac  
(5-100 mg/kg, i.p.)  
celecoxib (2.5-50 
mg/kg, i.p.) 
Protection ROS 
scavenging 
NO protection 
NO protection 
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Table 2. Continued 
 
Experimental model NSAIDs Outcome 
MPTP mouse (C57/BL/6) 
model of PD, MPTP (20 mg/kg i.p. 
four injections) 33].  
Rofecoxib (12.5-50 mg/kg, i.p. for 5 
days before and after  
Protection ↓COX-2 
MPTP mouse (C57/BL/6) 
model of PD, MPTP (20 
mg/kg i.p) [144]. 
Rofecoxib  Protection ↓COX-2 
MPTP mouse (C57/BL/6) 
model of PD, MPTP  
(60 mg/kg i.p) [41]. 
Rofecoxib (10 mg/kg, i.p.,  
for 21 days 1 day after  
the injury MPTP) 
NO protection 
MPP+ rat model of PD, 
intrastriatal (32 nmol  
in 1 µl) [146]. 
ASA (100 mg/kg, i.p. four  
injections, after MPP+ infusion) 
Paracetamol (100mg/kg, i.p.four 
injections, after  
MPP+ infusion) 
Protection ROS 
scavenging  
Partial protection ROS 
scavenging  
Rat mesencephalic 
neuronal cultures  
6-OHDA (2.5-10 µM) 
MPP+ (2.5-10 µM) [148]. 
Ibuprofen (25, 100, 250 µM) 
SC-560 (6.5 µM) NS-398 (5-50 
µM) and Cayman 
10404 (0.1-10 nM)  
Protection for both 
toxins ↓COX-2 
NO protection  
Protection against 
only 6-OHDA- 
toxicity ↓COX-2 
6-OHDA rat model of  PD, 
intrastriatal (22.5 µg) [147]. 
Celocoxib (20 mg/kg i.p., -1 up to 
+12 or 21 days) 
 
Protection ↓COX-2 
Primary mesencephalic 
mixed neuron-microglia 
cultures MPP+ (0.5 µM) [23]. 
DuP697 (10 nM) Protection ↓COX-2 
Rat model of PD,  
intrastriatal MPP+ or  
6-OHDA 1 mM (10 min  
1µl/min ) [108]. 
ASA (100 mg/kg i.p.) 
 
Meloxicam (50 mg/kg i.p.) 
Protection for both  
toxins ROS scavenging   
NO protection both toxins 
Rat model of PD,  
intranigral 1 mM  
(32 nmol in 1 µl) [149]. 
ASA (100 mg/kg i.p.) 
Paracetamol (100 mg/kg i.p.) 
Protection ROS 
scavenging and  
↓superoxide anion 
generation 
PC12 cells MPP+ 
(30 µM) [150]. 
Indomethacin (100 µM) 
Ibuprofen (100 µM) 
Ketoprofen (100 µM) 
Diclofenac (100 µM) 
ASA (100 µM) 
Potentiation  of  
neurotoxicity ↓MRP 
Potentiation of 
neurotoxicity ↓MRP 
Potentiation of 
neurotoxicity ↓MRP 
Potentiation of 
neurotoxicity ↓MRP 
No effect 
 
ASA and SA but not for indomethacin was identified as COX-independent and 
in volved specific inhibition of GLU-mediated induction of NF-κB, 
suggesting, for the first time, a link between neuroprotection and the nuclear 
event [117].  
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 Moreover, Aubin and colleagues [136] confirmed these ASA 
neuroprotective effects in a low dosage MPTP mouse model of PD. In 
accordance with the previous study, using an ex vivo and in vitro approach 
they found that the protective effect of ASA, its soluble lysine salt (Aspegic) 
and SA, is probably not due to COX inhibition. Their assertion was just a 
speculation based on the fact that other COX inhibitors such as paracetamol, 
diclofenac and indomethacin were ineffective. Likewise, the involvement of 
NF-κB was ruled out based on the lack of effect of dexamethasone, a 
glucocorticoid known to powerfully repress this nuclear factor function. ROS 
scavenging activity as a possible mechanism for explaining SA and ASA’s 
neuroprotection was instead proposed by these authors [136]. 
 In addition, SA was found to be neuroprotective, even if not completely, in 
a higher dosage MPTP mouse model of PD [137]. SA acted on both the 
terminal and cell body area of the nigrostriatal system as might be deduced by 
the pronounced effect against both MPTP-induced striatal DA depletion and 
loss of tyrosine hydroxylase (TH) immunereactive on nigral cell bodies. Ferger 
and colleagues in their paper pointed out that SA neuroprotective properties 
are based on its effective .OH scavenger rather than on its COX-inhibitory 
action [137].  
 This piece of evidence has been further confirmed by Mohanakumar et al. 
[138], in a MPTP mouse model of PD, where SA demonstrated a clear 
antioxidant action blocking toxin-induced glutathione (GSH) and DA depletion 
acting as a .OH scavanger in the brain and indicates its strength as a valuable 
neuroprotectant. SA did not inhibit MAO-B as has been previously shown by 
Aubin [136], overruling the possibility that its observed neuroprotective effects 
were caused by the possible blockade on the production of MPP+ from MPTP 
due to the presence of this enzyme in the brain. It is worth noting that these 
authors showed for the first time that SA pretreatment also significantly 
improved motor activity, blocking akinesia or catalepsy caused by MPTP 
administration [138].  
 An in vitro study evaluated the effects of some NSAIDs on cultured 
primary rat embryonic neurons from rat embryos mesencephalon also 
containing glial cells, an experimental preparation that reflects the cellular 
composition of the brain well, and is therefore useful in the study of 
neuroinflammation [139]. Incubation with ASA, paracetamol or ibuprofen 
protected DAergic neurons against GLU toxicity, considering as indices the 
reduction of the decrease in DA uptake caused by GLU, and the attenuation of 
the TH-positive cells loss. Among the NSAIDs tested, ibuprofen was the most 
effective and surprisingly increased the number of DA cells in basal condition 
most likely protecting them from the excitoxicity associated with culture 
medium change [139]. 
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 So far experimental evidence has suggested that NSAIDs act as 
neuroprotectants essentially through a nonclassical mechanism. Against the 
general trend, the role of COX-1 and COX-2 enzymes was reassessed by 
Teismann and Ferger [140], who proposed the use of COX-2 inhibitors as a 
new non-DAergic therapy for PD. Their assumption was based on the effects 
of ASA and meloxicam, the latter a preferential antagonist for the COX-2 
isoform, in a MPTP mouse model of PD. Both drugs, at higher dosages, 
showed an almost complete protection against MPTP toxicity. ASA and 
meloxicam antagonized MPTP-induced striatal DA depletion, attenuated the 
reduction of TH immunereactivity of the SNc and the MPTP-induced decrease 
in locomotor activity [140].  
 Carrasco and Werner [141], using a neuronally enriched mesencephalic 
culture system, showed that ASA was also able to increase the survival of DA 
neurons exposed to low doses of 6-OHDA and MPP+ but not to counteract the 
morphological changes induced by the toxins. However, the authors did not 
investigate the possible protective mechanism of ASA [141].  
 The role of inflammation in the pathogenesis of PD was studied for the 
first time by Kurkowska-Jastrzębska et al. [142] using indomethacin in a 
MPTP mouse model of PD. This drug protected SNc DA neurons against the 
toxin effect and it was associated with diminished microglial activation and 
lymphocytic infiltration in the damaged areas. Thus, reduced inflammation by 
indomethacin might result in less damage of DAergic neurons. However, in 
this study, microglial and lymphocytes accumulation was decreased only in 
association with less neuronal impairment, when indomethacin was given 
before MPTP. Indomethacin in higher dose or given 24 h after intoxication did 
not decrease inflammatory reaction. Therefore, the anti-inflammatory effect of 
indomethacin might be secondary to the diminished neural injury which 
probably results from a direct interaction of indomethacin maybe on neurons 
scavenging ROS. However, indomethacin appeared to be toxic in high doses 
indicating that doses of NSAIDs should be considered carefully in clinical 
trials [142]. 
 In view of conflicting reports so far on the role of the NSAIDs as 
neuroprotectants and the involvement of COX isoenzymes in their effects, 
Sairam et al. [143], used SA, diclofenac and celecoxib in a model of PD 
induced infusing MPP+  directly into the striata of rats. These three anti-
inflammatory agents have different mechanisms of action. SA is well-known 
to have an effect independent of the COX activity, diclofenac is a non-
selective reversible COX-inhibitor and celecoxib is instead a specific COX-2 
inhibitor. The failure of celecoxib and diclofenac to protect animals against 
MPP+-induced DA depletion, together with a significant attenuation of severe 
DA depletion (>65%) induced  by  SA indicate  the absence of the involvement 
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of prostaglandins (PGs) in MPP+ action. The authors conclude that the 
difference in neuroprotection among the NSAIDs used in the study is mostly 
dependent on their antioxidant activity [143]. 
 Further insights into the field have been provided by Teismann and 
colleagues [33] in a very elegant in vitro study from MPTP-treated mice and 
post-mortem PD samples. These researchers showed that COX-2 isoenzyme is 
up-regulated in the SNc DAergic neurons in both animal and human samples, 
COX-2-mediated neurodegeneration might be correlated to its catalytic activity 
through the production of prostaglandins and maybe also to the oxidation of 
catechols such as DA [112]. Treatment with rofecoxib, before and after MPTP-
injection, blocked the increase of PGE2 in the midbrain, doubled the number of 
the surviving TH-positive neurons, and prevented the rise in protein 
cysteinyldopamine, an index of DA quinones production. Surprisingly, neither 
pharmacological nor genetic abrogation of COX-2 activity mitigate 
inflammatory processes [112].  
 The neuroprotective effects of rofecoxib have also been shown by 
Klivenyi and colleagues [114] in MPTP model of PD in mice. They showed 
that the selective COX-2 inhibitor either alone or in combination with creatine, 
that facilitates metabolic channelling and shows antiapoptotic properties [145] 
protected against striatal DA depletions and loss of SN TH-immunoreactive 
neurons. Administration of rofecoxib with creatine produced significant 
additive neuroprotective effects against DA depletions. These results suggest 
that a combination of a COX-2 inhibitor with creatine might be a useful 
neuroprotective strategy for PD [144].  
 The work of Przybyłkowski and colleagues [41] is also noteworthy, they 
have shown, in the MPTP model of PD in mice, that rofecoxib has no 
neuroprotective effect when it is given after MPTP intoxication, even for a 
long period, revealing that the time of COX-2 inhibition is critical to achieve a 
protective effect. Consequently, COX-2 activity, prostaglandins production 
and oxygen species formation might not play a detrimental role in neuronal 
cells death, at least when the injury process has started already. Nonetheless, 
the inhibition of COX-2 activity could be harmful to neurons injured by 
MPTP. Indeed, the authors showed that, in later stages of injury, COX-2, 
through the formation of cyclopentenone prostaglandins derived from PGD2, 
may participate in the resolution of inflammation and even in the regeneration 
process [41]. 
 Otherwise, Maharaj et al. [146] showed that ASA given after MPP+ 
administration, completely blockaded MPP+-induced striatal DA depletion. 
Similar treatment with paracetamol resulted instead only in a partial protection. 
In both experimental conditions, rat brain homogenates and rats intranigrally 
treated  with  MPP+, ASA and paracetamol  acted mainly as antioxidants. They 
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were also capable of blocking .OH production and lipid peroxidation in vitro, 
but in this regard ASA was the weaker compared to paracetamol. In 
conclusion, ASA appears to offer itself as a prophylactic as well as an adjuvant 
therapy for PD and its neuroprotective effect is only partially mediated by ROS 
scavenging properties [146].  
 Sánchez-Pernaute and colleagues [147] in a 6-OHDA rat model of PD, 
showed that selective inhibition of COX-2 by treatment (pre and post lesion) 
with celocoxib is protective against the neurotoxin effect. The authors 
evaluated celocoxib effects using micro PET and immunohistochemical 
techniques, and observed a decrease in microglial activation in the striatum and 
ventral midbrain associated with a prevention of the progressive degeneration 
seen in the intrastriatal 6-OHDA retrograde lesioned rats treated with the 
vehicle. The benefit of COX-2 activity inhibition might be attributed to a 
selective decrease of the harmful glial cells and to the no effect on the 
protective astroglia. Celocoxib’s rescue of DA toxin-insulted neurons from 
death could be mediated by both neuronal and glial COX-2, but in any case the 
effect obtained by this drug is to create favourable conditions for the 
prevention of progressive neurodegenerative cascades during and after 
neuronal injury similar to that seen in PD [147]. 
 On the other hand, results obtained in cultures of embryonic rat 
mesencephalic neurons treated with 6-OHDA and MPP+ showed that these two 
neurotoxins act differently in the killing of DA neurons, neuronal COX-2 
activity and PG production is involved only in the 6-OHDA-neurotoxic effect 
whereas MPP+ toxicity does not require COX involvement [148]. This 
evidence comes from experiments carried out with ibuprofen, a non selective 
COX inhibitor, SC-560 a COX-1 selective inhibitor and two selective COX-2 
inhibitors, NS-398 and Cayman 10404, showing that COX-2, but not COX-1, 
is involved in 6-OHDA toxicity. Since ibuprofen attenuated both 6-OHDA and 
MPP+-neurotoxicity, the authors proposed that this drug has additional COX-
independent effects as yet not well identified [148]. Some discrepancies with 
the previous study have been reported by Wang et al. [23]. These authors 
found that MPP+ induces DAergic degeneration enhancing COX-2 expression 
in both glial and DA cells in primary mesencephalic mixed neuron-microglia 
cultures. Its toxicity is undoubtedly mediated through PGE2, the levels of 
which almost doubled. They observed that the COX-2 specific inhibitor 
DuP697, attenuates microgliosis by decreasing PGE2 production, and leads to 
the rescue DA neurons from a secondary lethal neurotoxicity attack [23]. 
Valdecoxib, an other selective COX-2 inhibitor, acted similarly in a mouse 
model of PD abating microglia activation and the consequential MPTP-induced 
toxicity, confirming that COX-2 and activated microglia play an important role 
in secondary injury of DA neurons. Moreover, these cellular protective effects of 
Inflammation and PD 177 
valdecoxib pretreatment were confirmed in the behavioural counterpart of the 
experimentation in which it also alleviated locomotor deficits induced by the 
toxin, assessed in open field and vertical activity [23]. 
 A recent study threw some light on this question by confirming that ASA 
has a protective effect against neuronal damage induced by intrastriatal 
infusion of MPP+ and 6-OHDA using a microdialysis approach in conscious 
rats [108]. What makes this study noteworthy, is that the ASA neuroprotective 
effect was evidenced in vivo, indeed, this has been observed only under in 
vitro and ex vivo conditions to date. Pretreatment of rats with ASA, protected 
DA neurons in both animal models (MPP+ and 6-OHDA-lesioned) as indicated 
by electrochemical and TH immunostaining evidence, whereas meloxicam, a 
selective COX-2 inhibitor, was devoid of any activity. The authors have 
confirmed these findings also in vitro, in a human neuroblastoma cell culture 
line. In fact, ASA, but not meloxicam, inhibited cell death induced by 
treatment with MPP+, in a dose-dependent manner (unpublished observation). 
The mechanism of action of ASA seemed to be different in each model since it 
was associated with ROS scavenging activity in the 6-OHDA model, but not in 
the MPP+ model that surprisingly did not induce any .OH formation at the 
concentration used in this study. Therefore, it is likely that the protective effect 
exerted by ASA, in vivo, may be due to inhibition of MPP+ toxicity at the cell 
level, possibly by blocking NF-kB or caspase activation, thus providing further 
evidence that the neuroprotective effect of NSAIDs might be independent from 
COX-2 inhibition. However, other mechanisms, such as .OH scavenging 
activity, as in the model of 6-OHDA-induced damage, cannot be ruled out 
[108].  
 Finally, Maharaj et al. [149] have provided novel information by 
highlighting the role of NSAID agents on a different molecular target, the 
mitochondrion. These authors studied the effect of MPP+ on striatal 
mitochondrial function and the ability of MPP+ to generate superoxide .OH 
and the effect of ASA and paracetamol. These NSAIDs prevented MPP+-
induced inhibition of the mitochondrial electron transport chain and complex 
I activity. In addition, ASA and paracetamol significantly attenuated MPP+-
induced superoxide anion generation. The results of this study suggest that 
these NSAIDs not only serve as .OH scavengers but also prevent 
mitochondrial dysfunction and subsequent superoxide anion generation 
[149].  
 Nevertheless, Morioka et al. [150], have shown that treatment with some 
NSAIDs might instead aggravate the neurodegenerative processes. Indeed, 
coincubation of PC12 cells with indomethacin, ibuprofen, ketoprofen, or 
diclofenac, markedly enhanced MPP+-induced cell death. This additive 
detrimental effect  was not observed after treatment    with ASA and NS-398, a 
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COX-2 selective inhibitor, that had no effects on the toxin action. The authors 
showed that the potentiating effect of some NSAIDs on MPP+-induced cell 
death was not associated with any of the classical and non, actions attributed to 
them so far (i.e., inhibition of COX enzymes, ROS scavenging, antagonism at 
PPARγ, caspase-3-apoptotic cell death pathway). The possible mechanism 
whereby NSAIDs potentate MPP+-induced cell death might be the increase of 
intracellular accumulation of MPP+. In fact, these drugs suppressed the cellular 
efflux of MPP+ by the blockade of multidrug resistance proteins (MRP) [150]. 
 The use of different experimental conditions (i.e., in vivo versus in vitro, 
ex vivo, species or strain of animal used, cell types) drugs (NSAIDs are a 
heterogeneous chemical group also with different potency in crossing the 
blood-brain barrier), therapy duration (i.e., pre-treatment versus post-treatment 
or combination of both), time of observation, dose and type of neurotoxins 
used, may explain the differences among the studies here reviewed and, 
sometimes, the conflicting results. Overall, there is no doubt that ASA, SA, 
ibuprofen and especially COX-2 selective inhibitors exert neuroprotective 
effects, although the mechanism through which they act still remains 
controversial. Notwithstanding, the blockade of COX-2 activity seems to be 
essential for their effect. Their broad sites of action and pharmacological 
effects (from anticancer to antipyretic) might be the basis on which their 
efficacy in neurodegnerative disease is founded.  
 
Neuroprotective effects of NSAIDs in Parkinson’s 
diseases: Epidemiological evidence 
 Despite the evidence of inflammation in the brains of patients with PD, 
confirmed successively in animal models of PD, since the mid 1990s, NSAIDs 
have not yet been formally tested in PD. Hitherto, only five epidemiological 
studies have been carried out analyzing the association between regular use of 
NSAIDs and the risk of PD with conflicting results (Table 3).  
 
Table 3. Epidemiological studies of NSAIDs and PD. 
 
Study  Duration  
NSAIDs 
use 
Overall  
cohort 
PD 
cases 
Relative  
risk 
95% CI 
Chen et al., 2003 [151] >14 years 142,902 415 0.55 0.32-0.96 
Chen et al., 2005 [153] 8 years 146,565 413 0.65 0.48-0.88 
Case control 
Hernán et al., 2006 [154] 
>3 years 
 
 
7,896 
women 
men 
1,258 
493 
765 
0.93 
1.21 
0.79 
0.80-1.08 
0.95-1.54 
0.65-0.96 
Bower et al., 2006 [157] 20 years 404 202 0.50 0.20-1.5 
Ton et al., 2006 [159] 20 years 589 206 0.90 0.59-1.35 
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 The first piece of evidence was provided by Chen et al. [151] from the 
Harvard School of Public Health. They published the first study investigating 
prospectively the potential benefit in humans of the use of NSAIDs in reducing 
the risk of PD. These researchers found that regular users of these drugs had a 
lower risk of PD than non-users. The study was conducted among participants 
in the Health Professionals Follow-Up Study and the Brigham and Women’s 
Hospital based Nurses Health Study who were free of PD, stroke or cancer at 
the start of the research. More than 44,000 men and nearly 99,000 women were 
followed for 14 years and 18 years, respectively. Use of ASA and non-ASA 
NSAIDs (such as, diflunisal, ibuprofen, indomethacin, naproxen) was assessed 
via biennial questionnaires. A total of 236 men and 179 women developed PD 
during the course of the study. The risk of developing PD was 45% lower 
among regular users of non-ASA NSAIDs compared to non-users (pooled 
multivariate relative risk (RR), 0.55; 95% confidence interval (CI), 0.32-0.96). 
Regular use of non-ASA NSAIDs was reported by 6.1% of the men at the 
beginning of the study and 3.7% of the women. A similar decrease in risk was 
also found among participants who took two or more tablets of ASA per day 
compared to non-users (RR, 0.56; 95% CI, 0.26-1.21). No benefit was found 
among those who took smaller amounts of ASA per day or paracetamol. 
Additionally, increasing benefits were observed with longer duration of use of 
non-ASA NSAIDs [151]. It is worth noting, that the Chen study may 
underestimate the protective effect of NSAIDs, since PD is much more 
common in people over 75 years old, an age group not included in the Chen 
team’s data. Therefore, benefits of even greater magnitude might be 
demonstrable if this intervention were applied to the same population as it aged 
beyond 75 years. Moreover, these data provide little support for the routine use 
of NSAIDs as disease-modifying agents in PD, since to prevent one additional 
case of PD 98 individuals would have to be treated with them [152].  
 A subsequent prospective study conducted by the same group has provided 
further insights [153]. Chen and coinvestigators continued examining the 
relationship between NSAIDs use and risk of PD this time, utilizing another 
large cohort, the American Cancer Society's Cancer Prevention Study II 
Nutrition Cohort of 146,565 people. Between 1992 and 2000 they recorded 
413 new cases of PD in the cohort. Ibuprofen was associated with 35% lower 
risk of PD (RR, 0.65; CI 95% 0.48-0.88), with similar risk reductions for men 
and women and regardless of age or smoking status. There was a significant 
trend for lower risk with increasing consumption of ibuprofen (from RR 0.73 
with fewer than 2 tablets per week to RR 0.61 for daily use) but duration of use 
made little difference. In contrast to the previous study, no significant 
associations were found for ASA, other NSAIDs or paracetamol [153]. These 
discrepancies might be simply explained by the fact that considerably more people 
Arcangelo Benigno et al. 180
in the cohort used ibuprofen than other medications. However, the authors also 
did not exclude that there may be an ibuprofen-specific effect against PD, 
related to its unique molecule. Furthermore, another limitation of this study is 
that because ibuprofen is an over-the-counter medication, the so-called 
“nonusers” could have taken ibuprofen years ago, therefore, a short-term 
clinical study might not give complete data. Instead, long-term data would be 
necessary to more fully discern users and nonusers.  
 Recently, another group from the Harvard School of Public Health, has 
conducted a case-control study on subjects with no history of PD or 
parkinsonism-related drug use at baseline [154]. Their study was nested within 
a cohort of the world's largest computerised database, the British General 
Practice Research Database (GPRD). The authors analyzed 1,258 PD cases and 
6,638 controls, and reported a surprising finding: nonASA NSAIDs use 
reduces PD risk only in men but not in women. Use of nonASA NSAIDs was 
associated with a 20% reduction in the incidence of PD among men (odds ratio 
(OR), 0.79; CI 95% 0.65-0.96), and a 20% increase in the incidence of PD 
among women (OR, 1.21; CI 95% 0.95-1.54) [154]. Although sex differences 
in PD risk have been previously reported for caffeine consumption [155] and 
alcoholism [156], this was an unexpected finding that warrants further 
research.  
 Less promising insights have been provided by Bower and colleagues 
[157] from the Mayo Clinic College of Medicine in Rochester, Minnesota. 
They explored the association of PD with the use of NSAIDs in a population-
based, case-control study for a total of 392 individuals. The investigators used 
the medical records linkage system of the Rochester Epidemiology Project to 
identify 196 subjects who developed PD from 1976 to 1995. Consistent with 
the previous epidemiological studies [151,153,154], Bower and colleagues 
found that cases of PD used NSAIDs (excluding ASA) less frequently than 
controls (OR 0.5; CI 95% 0.2-1.5); however, the difference did not reach 
significance. This trend finding was similar for both NSAIDs and steroidal 
agents considered separately. The use of ASA was not significantly associated 
with PD as shown previously [153,154]. These investigators also showed a 
significant association between pre-existing immune-mediated diseases and the 
later development of PD (OR 1.8; 95% CI: 1.1-3.1). The association was 
stronger for women and for earlier onset of PD cases, but neither of these 
differences reached significance. These results support the hypothesis that 
there is an inflammatory component in the pathogenesis of PD and provide a 
rationale for the use of NSAIDs as neuroprotectants capable of delaying onset 
or slowing progression of the disease [157]. Since patients with diseases of 
immediate-type hypersensitivity are genetically predisposed to initiate a 
humoral response to low levels of antigens, they might also be predisposed to 
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initiate neuroinflammatory responses as well and play a role in the aetiology of 
PD [158].  
 The latest available data on the subject come from Ton and colleagues 
[159] from the University of Washington and, unfortunately, they have 
continued in dampening the initial enthusiasm. In fact, in an American 
population-based case-control study these investigators did not observe a 
significant association between PD and NSAIDs. Subjects among enrolees of a 
health maintenance organization included 206 cases between ages 35 and 89 
with a new diagnosis of idiopathic PD between 1992 and 2002, and 383 
randomly selected controls. Exposure to NSAIDs was ascertained from an 
automated pharmacy database. After adjusting for age, sex, smoking, duration 
of enrolment, and clinic, the risk of PD among individuals who received non-
ASA NSAIDs between 1977 and 1992 was 0.90 (95% CI: 0.59-1.35) and 1.67 
(95% CI: 0.60-4.60) between 1993 and 2002. Use of ibuprofen was not 
associated with PD (OR: 0.89; 95% CI: 0.60-1.32). The risk of PD associated 
with ASA or ASA-containing medications was 0.74 (95% CI: 0.49-1.12). These 
results provide only limited support for the hypothesis that use of ASA may reduce 
the risk of this disease, but this association was statistically imprecise and no clear 
trend according to number of ASA prescription was observed. In addition, no 
indication at all of protection from other NSAIDs was revealed [159].  
 Differences in the methods of ascertaining medication exposures, in the 
extent or timing of exposure to NSAIDs, as well as chance, may account for 
the discrepant findings from this and the earlier studies. These findings offer, 
at most, a limited support for the hypothesis of neuroprotection from ASA, and 
no indication of protection from other NSAIDs. Larger studies that include 
medication records and over-the-counter medication use will clarify these 
associations. Nevertheless, these unclear indications must be clarified and 
corroborated by clinical trial before any firm conclusions can be drawn. 
Furthermore, the role of selective COX-2 inhibitors might be investigated 
since only the effect of traditional NSAIDs has been analysed by 
epidemiological studies. In fact, selective COX-2 inhibitors have not been in 
use long enough for epidemiological data to be collected. Moreover, the side 
effects of NSAIDs therapy, such as gastrointestinal lesions and cardiovascular 
risks should be carefully evaluated.  
 
Conclusions and implications 
 From the large amount of literature here reviewed it appears evident that 
inflammatory processes are involved in the pathophysiology of PD. 
Neuroinflammation, a processes orchestrated and sustained by activated 
resident microglia cells, might be contributing to the demise of nigral DA cells, 
perpetuating the neurodegenerative phenomenon. A large body of information 
on the molecular and cellular mechanisms whereby inflammation might induce 
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neuronal death has been generated in the past few years by researchers in the 
neuroscience community. Nevertheless, further clarification of the role of 
inflammation in the pathophysiology of basal ganglia disorders is required, 
since the overall picture is still confusing. Complicating the situation is the fact 
that inflammation is a double-edged sword and probably starts as a beneficial 
defence mechanism that at some point evolves into a destructive and 
uncontrollable chronic reaction. Thus, the ideal approach would be to inhibit 
the deleterious effects associated with neuroinflammation while preserving the 
inflammatory pathways that lead to neuroprotection. From the above 
discussion it seems clear that drugs inhibiting inflammation and microglial 
activation might be an important feature of the treatment of PD and also the 
dementia, often associated with the disease [28,30,73,74,160]. Consequently, a 
rational use of NSAIDs could be useful as therapeutic intervention in PD and 
in other major neurological diseases with similar etiopathology, such as AD, 
ASL and MS. Nonetheless, despite the fact that experimental and 
epidemiological evidence has been provided for future use of anti-
inflammation agents, they have not been rigorously corroborated in trial 
studies for the treatment of motor disorders as yet. Furthermore, most of the 
data have yielded contradictory results. This may be a result of the peculiar 
characteristics of these drugs, so different both at the chemical and action 
level. In fact, NSAIDs might exert their neuroprotective actions not only 
inhibiting COX enzymes but also by acting on NF-κB, iNOS, PPARγ, 
suppressing the formation of DA quinones, scavenging ROS and RNS activity 
and probably by other unknown mechanisms. Indeed, recently it has also been 
proposed that anti-inflammatory compounds might act inhibiting microglial 
proliferation, modulating the cell cycle progression and apoptosis [161]. 
 NSAIDs are sui generis, and the further anti-inflammatory agents research 
progresses, the greater the number of indications that are discovered. NSAIDs 
have carved out a unique career in such diverse fields as the treatment of pain, 
migraine, prevention of cardiovascular disorders, and the chemoprophylaxis of 
various types of cancer. Probably, we are at the threshold of a new promising 
career for the NSAIDs especially in prevention of neurodegenerative disease 
rather than for their treatment. Indeed, it is quite possible that NSAIDs are 
ineffective once the pathological process has started, the pharmacological 
intervention should start very early in the pre-symptomatic period, according 
to some experimental a epidemiological evidence [41,151,153,154]. This need 
is also corroborated by the recent failure of some promising clinical trials in 
AD [162,163] shedding some doubts on the inflammation hypothesis of AD. 
Thus, the attractive thesis that NSAIDs might protect the remaining surviving 
DA neurons from the degeneration process and thus slow the ratio of progression 
of  the illness sounds less promising. Due to the complexity of  the disease, it is 
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possible that combination therapy, concomitant use of agents with nonoverlapping 
or even synergistic mechanisms of action, may represent the best means 
available to enhance treatment effectiveness. Some results could be achieved, 
therefore, by combining NSAIDs with other rescue agents, such as MAO inhibitors 
(rasagiline, safinamide); mitochondrial function enhancers (coenzyme Q10, 
creatine); antiapoptotic agents; protein aggregation inhibitors and neurotrophic 
factors [164]. Although this hypothesis is worthy of consideration, it remains 
largely undocumented and certainly deserves further discussion. Furthermore, 
NSAIDs might be a beneficial adjuvant to L-DOPA therapy counteracting the 
toxicity induced by its long-term use, through anti-inflammatory action and the 
reduction of DA quinones generated by L-DOPA therapy itself [112]. 
 There are also many avenues that remain unexplored, so there are 
undoubtedly further advances to be made. In the next few years, we believe 
that novel approaches [164,165] will support the current dopamine-
replacement therapy for PD. Furthermore, early diagnosis, early symptomatic 
treatment and particularly the introduction of neuroprotective therapies will 
improve PD pharmacological management. Indeed, disease modification 
remains the most important goal in PD. Consequently, compounds inhibiting 
neuroinflammation such as NSAIDs represent an important starting point that 
could lead us to the identification for the first time of disease-modifying agents 
for this devastating disease.  
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